• 1
    Tiollais P, Buendia M. Hepatitis B virus. Sci Am 1991; 246:116123.
  • 2
    Maynard JE. Hepatitis B: global importance and need for control. Vaccine 1990; 8(Suppl:S18S20.MEDLINE
  • 3
    Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effects of alpha-interferon treatment in patients with hepatitis B e antigen positive chronic hepatitis B: a meta-analysis. Ann Intern Med 1993; 119:312323.MEDLINE
  • 4
    Severini A, Liu XY, Wilson JS, Tyrrell DLJ. Mechanism of inhibition of duck hepatitis B virus polymerase by (−)-β-L-2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 1995; 39:14301435.MEDLINE
  • 5
    Dienstag JL, Perillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic viral hepatitis B infection. N Engl J Med 1995; 333:16571661.MEDLINE
  • 6
    Tyrrell DLJ, Mitchell MC, de Man RA, Schalm SW, Main J, Thomas HC, Fevery J, et al. Phase II trial of lamivudine for chronic hepatitis B [Abstract]. Hepatology 1993; 18:112A.
  • 7
    van Leeuwen R, Katlama C, Kitchen V, Boucher CA, Tubiana R, McBride M, Ingrand D, et al. Evaluation of safety and efficiency of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study. J Infect Dis 1995; 171:11661171.MEDLINE
  • 8
    Schuurman R, Nijhuis M, van Leeuwen R, Schipper P, de Jong D, Collis P, Danner SA, et al. Rapid changes in human immundeficiency virus type I RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 1995; 171:14111419.MEDLINE
  • 9
    Tisdale M, Kemp SD, Parry NR, Larder BS. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci U S A 1993; 90:56535656.MEDLINE
  • 10
    Darby G, Field HJ, Salisbury AS. Altered substrate specificity of herpes simplex virus thymidine kinase confers acyclovir resistance. Nature 1981; 289:8183.MEDLINE
  • 11
    Field HJ, Darby G. Pathogenicity in mice of herpes simplex viruses which are resistant to acyclovir in vitro and in vivo. Antimicrob Agents Chemother 1980; 17:209216.MEDLINE
  • 12
    Bartholomew MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson LC, Bunzendahl H, Condreay LC, et al. Hepatitis B virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997; 349:2022.MEDLINE
  • 13
    Ling R, Mutimer D, Ahmed M, Boxall HE, Elias E, Dusheiko GM, Harrison TJ. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996; 24:711713.MEDLINE
  • 14
    Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DLJ. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996; 24:714717.MEDLINE
  • 15
    Kaneko S, Miller RH, Fienstone SM. Detection of serum hepatitis B virus DNA in patients with chronic hepatitis using the polymerase chain reaction assay. Proc Natl Acad Sci U S A 1989; 86:312316.MEDLINE
  • 16
    Fallows DA, Goff SP. Mutations in the epsilon sequences of human hepatitis B virus affect both RNA encapsidation and reverse transcription. J Virol 1995; 69:30673073.MEDLINE
  • 17
    Galibert F, Mandart E, Fitoussi F, Tiollais P, Charnay P. Nucleotide sequence of the hepatitis B virus genome (subtype ayw ) cloned in E. coli. Nature 1979; 281:646650.MEDLINE
  • 18
    Sells MA, Chen ML, Acs G. Production of hepatitis B virus particles in HepG2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci U S A 1987; 84:10051009.MEDLINE
  • 19
    Jansen RW, Johnson LC, Averett DR. High-Capacity in vitro assessment of anti-hepatitis B virus compound selectivity by a virion-specific polymerase chain reaction assay. Antimicrob Agents Chemother 1993; 37:441447.MEDLINE
  • 20
    Furman PA, Davis M, Liotta DC, Paff M, Frick LW, Nelson DJ, Dornsife RE, et al. The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (−) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxanthiolan-5-yl] cytosine. Antimicrob Agents Chemother 1992; 36:26862692.MEDLINE
  • 21
    Li MD, Bronson DL, Lemke TD, Faras AJ. Phylogenetic analyses of 55 retroelements on the basis of the nucleotide and product amino acid sequences of the pol gene. Mol Biol Evol 1995; 12:657670.MEDLINE
  • 22
    Johnson MS, McClure MA, Feng DF, Gray J, Doolittle RF. Computer analysis of retroviral pol genes: assignment of enzymatic functions to specific sequences and homologies with nonviral enzymes. Proc Natl Acad Sci U S A 1986; 83:76487652.MEDLINE
  • 23
    Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz AT. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992; 256:17831790.MEDLINE
  • 24
    Jacobo-Molina A, Ding J, Nanni RG, Clark AD, Lu X, Tantillo C, Williams RL, et al. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. Proc Natl Acad Sci U S A 1993; 90:63206324.MEDLINE
  • 25
    Fischer KP, Tyrrell DLJ. Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine ((−)-beta-L-2′,3′-dideoxy-3′-thiacytidine) in vitro. Antimicrob Agents Chemother 1996; 40:19571960.MEDLINE
  • 26
    Dienstag JL, Schiff ER, Mitchell M, Gitlin N, Lissoos T, Condreay L, Garrett L, et al. Extended lamivudine retreatment for chronic hepatitis B [Abstract]. Hepatology 1996; 24:188A.
  • 27
    Larder BA, Kemp SD, Harrigan PR. Potential mechanism of sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995; 269:696699.MEDLINE
  • 28
    Back NKT, Nijhuis M, Keulen W, Boucher CAB, Oude Essink BB, van Kuilenburg ABP, van Gennip AH, et al. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J 1996; 15:40404049.MEDLINE